Enzo Biochem Suit Ends with $35 Million Payment
Of the 11 suits filed alleging infringement of the ‘197 patent, 7 were against diagnostics companies and 4 were against instrument firms. Enzo previously announced settlements resulting in payments by Affymetrix (see IBO 10/31/15) and Agilent Technologies (see IBO 5/15/16). The case against Illumina is still before the court.
New York, NY 5/16/16—Enzo Life Sciences, a subsidiary of Enzo Biochem, will receive a $35 million payment as part of a settlement with Thermo Fisher Scientific (formerly Life Technologies) in its suit alleging infringement of US Patents Nos. 6,992,180 (Oligo- or Polynucleotides Comprising Phosphate Moiety Labeled Nucleotides) and 7,064,197 (System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids) (see IBO 4/30/12). The suit was 1 of 11 filed by Enzo regarding the ‘197 patent, 4 of which have been resolved.
